Increased Demand for Vyvgart Boosted Argenx SE (ARGX) in Q4

1 month ago 18

Soumya Eswaran

Fri, February 6, 2026 astatine 7:33 AM CST 3 min read

Baron Funds, an concern absorption company, released its fourth-quarter capitalist missive for the “Baron Health Care Fund”. A transcript of the missive tin beryllium downloaded here. The money roseate 13.10% (Institutional Shares) successful the quarter, compared to a 11.92% summation for the Russell 3000 Health Care Index (benchmark) and a 2.40% summation for the Russell 3000 Index (the Index). The Fund returned 10.28% for the afloat year, compared to 14.56% and 17.15% gains for the indexes, respectively. Strong banal enactment successful biotechnology contributed to the Fund’s comparative gains successful the quarter. The Fund seeks to put successful businesses with secular maturation opportunities, a sustainable competitory edge, and beardown management. The steadfast believes that healthcare is simply a beardown assemblage successful the U.S. economy, offering charismatic concern opportunities with affirmative momentum heading into 2026. Please reappraisal the Fund’s apical 5 holdings to summation insights into their cardinal selections for 2025.

In its fourth-quarter 2025 capitalist letter, Baron Health Care Fund highlighted stocks specified arsenic Argenx SE (NASDAQ:ARGX). Argenx SE (NASDAQ:ARGX) is simply a commercial-stage biopharma institution and a starring contributor to the fund's quarterly performance. The one-month instrumentality of Argenx SE (NASDAQ:ARGX) was 4.04%, and its shares gained 26.86% of their worth implicit the past 52 weeks. On February 5, 2026, Argenx SE (NASDAQ:ARGX) banal closed astatine $820.31 per share, with a marketplace capitalization of $50.764 billion.

Baron Health Care Fund stated the pursuing regarding Argenx SE (NASDAQ:ARGX) successful its 4th fourth 2025 capitalist letter:

"Argenx SE (NASDAQ:ARGX) is simply a biotechnology institution champion known for processing Vyvgart, the starring FcRn inhibitor for the attraction of autoimmune conditions. Shares roseate arsenic Vyvgart income meaningfully exceeded capitalist expectations. Our conversations with absorption and neurologists proceed to reenforce Vyvgart’s worth arsenic an important attraction enactment with beardown semipermanent maturation potential. The cause continues to motorboat good successful generalized myasthenia gravis, and its motorboat successful chronic inflammatory demyelinating polyneuropathy is disconnected to a beardown start. Over time, we expect Vyvgart to show efficacy crossed an expanding scope of autoantibody-driven autoimmune conditions, and we are excited by argenx’s pipeline advancement and upcoming Phase 3 readouts for Vyvgart successful myositis and empasiprubart successful multifocal centrifugal neuropathy."

Is argenx SE (ARGX) the Best Cancer Stock to Invest successful for Long-Term Gain?

Argenx SE (NASDAQ:ARGX) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 50 hedge money portfolios held Argenx SE (NASDAQ:ARGX) astatine the extremity of the 3rd quarter, up from 53 successful the erstwhile quarter. While we admit the imaginable of Argenx SE (NASDAQ:ARGX) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.